Sirio Pharma's (SZSE:300791) Solid Earnings Are Supported By Other Strong Factors
Sirio Pharma Co., Ltd. (SZSE:300791) just reported healthy earnings but the stock price didn't move much. We think that investors have missed some encouraging factors underlying the profit figures.
An Intrinsic Calculation For Sirio Pharma Co., Ltd. (SZSE:300791) Suggests It's 24% Undervalued
Key Insights Sirio Pharma's estimated fair value is CN¥51.11 based on 2 Stage Free Cash Flow to Equity Sirio Pharma is estimated to be 24% undervalued based on current share price of CN¥39.07 Ana
Xianle Health (300791.SZ) released 2023 annual results, with net profit of 281 million yuan, an increase of 32.39% over the previous year
Xianle Health (300791.SZ) released its 2023 annual report. The company achieved operating income of 35 during the reporting period...
Softgel Capsules Market Size, Share & Trends Analysis Report 2023-2030, Featuring Fuji Capsule, Sirio Pharma, CAPTEK Softgel, Catalent, EuroCaps, Aenova, ProCaps Laboratories and Soft Gel Technologies
Xianle Health (300791.SZ): The repurchase was completed with a cumulative cost of 398.997 million yuan to repurchase 1.285,600 shares
Gelonghui, March 19, 丨 Xianle Health (300791.SZ) announced that as of March 18, 2024, the company had repurchased 1.285,600 shares of the company's shares through a dedicated securities account, accounting for 0.71% of the company's current total share capital of 181,562,337 shares. The highest transaction price was 35.88 yuan/share, the minimum transaction price was 25.29 yuan/share, and the total transaction amount was RMB 398.997 million (excluding transaction fees). At this point, the implementation of the company's share repurchase plan has been completed.
Zheng Liqun, Deputy General Manager and Secretary of the Board of Directors of Xianle Health (300791.SZ), increased her holdings by 27,700 shares
Xianle Health (300791.SZ) announced that Zheng Liqun, the company's deputy general manager and secretary of the board of directors, will implement the plan to increase her holdings...
Sirio Pharma Co., Ltd. (SZSE:300791) Surges 7.0%; Private Companies Who Own 43% Shares Profited Along With Insiders
Key Insights The considerable ownership by private companies in Sirio Pharma indicates that they collectively have a greater say in management and business strategy 53% of the business is held by th
Take Care Before Diving Into The Deep End On Sirio Pharma Co., Ltd. (SZSE:300791)
There wouldn't be many who think Sirio Pharma Co., Ltd.'s (SZSE:300791) price-to-earnings (or "P/E") ratio of 25.3x is worth a mention when the median P/E in China is similar at about 27x. However, i
Sirio Pharma's (SZSE:300791) Returns On Capital Not Reflecting Well On The Business
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earn
Xianle Health (300791.SZ) plans to set up an industrial fund to focus on investing in China's big health sector
Xianle Health (300791.SZ) issued an announcement. The board of directors of the company agreed that the company and Shanghai Hongzhang Investment Management Co., Ltd...
Xianle Health (300791.SZ): Currently, the company's hard capsule business volume is small
Gelonghui January 5 丨 Some investors asked Xianle Health (300791.SZ) on the investor interactive platform, “Has the price of the company's raw hollow vegetable capsule shell increased? Is there a big impact on costs?” The company replied that hollow vegetable capsule shells are mainly used for hard capsule products. Currently, the company's hard capsule business volume is small, and fluctuations in the price of this raw material have very little impact on the company's costs.
Xianle Health (300791.SZ): A total cost of 30.984,400 yuan to buy back 999,200 shares
Gelonghui, January 2, 丨 Xianle Health (300791.SZ) announced that as of December 31, 2023, the company had repurchased 999,200 shares of the company's shares through a special stock repurchase account, accounting for 0.55% of the company's current total share capital of 181,562,320 shares. The highest transaction price was 35.80 yuan/share, the minimum transaction price was 25.29 yuan/share, and the total transaction amount was 30,984,400 yuan (excluding transaction fees).
Is Sirio Pharma (SZSE:300791) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Xianle Health (300791.SZ): Repurchased 887,400 shares at a total cost of RMB 27.0712 million
Gelonghui on December 4 | Xianle Health (300791.SZ) announced that as of November 30, 2023, the company has repurchased 887,400 shares of the company through a special stock repurchase account through centralized bidding transactions, accounting for 0.49% of the company's current total share capital of 180,497,320 shares. The highest transaction price is 35.75 yuan/share, the lowest transaction price is 25.29 yuan/share, and the total transaction amount is 27.0712 million yuan (excluding transaction fees).
Do Its Financials Have Any Role To Play In Driving Sirio Pharma Co., Ltd.'s (SZSE:300791) Stock Up Recently?
Sirio Pharma's (SZSE:300791) stock is up by a considerable 37% over the past three months. As most would know, fundamentals are what usually guide market price movements over the long-term, so we de
Xianle Health (300791.SZ) granted 1.24 million restricted shares for the first time to 76 incentive recipients
Xianle Health (300791.SZ) issued an announcement, the company “Xianle Health Technology Co., Ltd. 2023 period...
Xianle Health (300791.SZ): Repurchased 0.25% of shares at a cumulative cost of RMB 12.43 million
Gelonghui November 1丨Xianle Health (300791.SZ) announced that as of October 31, 2023, the company has repurchased 452,100 shares of the company through a special stock repurchase account through centralized bidding transactions, accounting for 0.25% of the company's current total share capital of 180,497,320 shares. The highest transaction price is 31.50 yuan/share, the lowest transaction price is 25.29 yuan/share, and the total transaction amount is 12,430,492.88 yuan.
[Instant Analysis of BT Financial Report] Xianle Health 2023 Third Quarter Report: The balance ratio has risen slightly, operating income has increased significantly, and net cash flow has declined
This financial report was announced: 2023-10-25 16:16:29 Xianle Health (stock code: 300791) is a company operating in the nutrition and health industry. It mainly improves the health level of the body and reduces the risk of disease by supplementing essential nutrients and bioactive substances for the human body. As people pay more attention to health and the nutritional health food industry develops rapidly, Xianle Health Company will benefit from the rapid development of the industry and the continuous attention of consumers to health. In terms of assets and liabilities, Xianle Health's total assets for the third quarter of 2023 were 4.903 billion yuan, compared to the end of the previous year
Xianle Health (300791.SZ): Net profit of 185 million yuan for the first three quarters increased 5.1% year-on-year
Glonghui, Oct. 25丨Xianle Health (300791.SZ) announced its third quarter report. Revenue was 2.5 billion yuan, up 39.96% year on year, net profit was 185 million yuan, up 5.1% year on year, after deducting non-net profit of 180 million yuan, up 14.49% year on year, and basic earnings per share were 1.03 yuan.
Sirio Pharma (SZSE:300791) Could Be Struggling To Allocate Capital
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an e
No Data